第一个单密集型质子疗法中心的儿科经验和结果
Stephanie M Perkins1, Sabrina Prime1, Michael Watts1
1S. Lee Kling Proton Therapy Center, Washington University School of Medicine/Siteman Cancer Center, Saint Louis, MO 63110, USA.
Cancers
|August 26, 2023
概括
第一个紧的质子疗法中心成功治疗了250名儿科患者,证明了各种人群的优异生存率和可访问性,包括那些患有中枢神经系统癌症的人群.
科学领域:
- 辐射瘤学 辐射瘤学
- 儿科瘤学 儿科瘤学
- 医学物理 医学物理
背景情况:
- 紧的质子疗法中心的出现为儿童癌症治疗提供了新的可能性.
- 学术辐射瘤学系优先考虑儿科护理,整合诸如质子疗法等先进技术.
研究的目的:
- 评估在第一个单密集中心用质子疗法治疗的儿科患者的患者和瘤特征.
- 评估治疗结果,包括生存率和资源利用率,用于儿科质子疗法.
主要方法:
- 在2013-2022年期间治疗的250名儿科患者 (≤21岁) 的回顾性分析.
- 数据收集包括患者的人口统计,瘤类型,治疗细节 (如麻醉,行驶距离),保险和社会经济状况.
- 进行了生存分析,以确定3年后的总生存率.
主要成果:
- 儿科患者占总质子疗法容量的18%.
- 中枢神经系统 (CNS) 瘤是最常见的 (69.6%),32%需要脊辐射.
- 观察到83.7%的优异的3年整体存活率,中枢神经系统患者的结果更好;没有报告二次恶性瘤.
结论:
- 第一个紧的质子疗法中心成功地扩大了儿童癌症治疗的机会,使多样化的患者群体获得治疗.
- 质子疗法是一种可行的,有效的治疗儿科癌症,包括复杂的中枢神经系统病例.
- 数据提供了对患者个人资料和建立儿科质子疗法服务的资源需求的见解.
更多相关视频
05:08Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model
Published on: February 17, 2019
6.2K
07:57Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
Published on: March 24, 2022
2.8K
相关概念视频
Positron Emission Tomography
4.3K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
4.3K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
